
Join the All of Us Research Program...
The All of Us research program, part of the Precision Medicine Initiative through the National Institutes of Health (NIH), is an...
Program for the Assessment of Clinical Cancer Tests (PACCT-1): Trial Assigning Individualized Options for Treatment: The TAILORx Trial
TAILORx is the first trial that has been developed as a result of the NCI’s “Program for the Assessment of Clinical Cancer Tests,” (PACCT). The study population will include patients with estrogen-receptor (ER) positive, axillary lymph node negative breast cancer. The Oncotype DX test being used in TAILORx is a 21 gene RT-PCR-bases assay that may be performed on routinely processed, formalin-fixed, paraffin embedded tissue.
Contact Meagan Fair at 508-595-2204 for more information.
For more information about this study:
https://clinicaltrials.gov/ct2/show/study/NCT00310180#locn